Literature DB >> 14641505

Cost of a recurrent vs. cost of first-ever stroke over an 18-month period.

J-F Spieler1, G De Pouvourville, P Amarenco.   

Abstract

When assessing the cost-effectiveness of the secondary prevention of stroke, it is not well known whether the cost of a recurrent brain infarction (BI) is different from a first-ever BI. In a cohort of 435 consecutive prevalent cases of BI (including both recurrent and first-ever BI) we collected medical and socio-economic variables. Handicap was measured with the Rankin scale. Only the direct medical costs were considered over an 18-month period from a societal perspective. We compared first-ever to recurrent BI. Of the 435 patients 20.5% had a recurrent BI. The length of the initial hospitalization and the distribution of the patients into the three classes of handicap (Rankin 0-2, 3, and 4-5) were similar in the first-ever and recurrent BI groups. The average total cost of a first-ever BI was euro 19 725 (95% CI, 17 950-21 501) and euro 18 560 (95% CI, 15 798-21 322) for a recurrent BI (P = 0.48). There were no differences between the two groups when the costs were compared by handicap levels (P = 0.17) or when the costs were compared for each type of expenditure (initial hospitalization, rehabilitation, ambulatory services) except for long-term care, because of the small number of cases. This study suggests that the costs of recurrent BI are roughly similar to the costs of first-ever BI, which may be helpful when studying the cost-effectiveness of secondary stroke prevention trials.

Entities:  

Mesh:

Year:  2003        PMID: 14641505     DOI: 10.1046/j.1468-1331.2003.00665.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  Economic burden of stroke: a systematic review on post-stroke care.

Authors:  S Rajsic; H Gothe; H H Borba; G Sroczynski; J Vujicic; T Toell; Uwe Siebert
Journal:  Eur J Health Econ       Date:  2018-06-16

2.  [Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke].

Authors:  Christa Claes; Thomas Mittendorf; Martin Grond; Johann-Matthias Graf von der Schulenburg
Journal:  Med Klin (Munich)       Date:  2009-01-23

3.  Program of rehabilitative exercise and education to avert vascular events after non-disabling stroke or transient ischemic attack (PREVENT Trial): a multi-centred, randomised controlled trial.

Authors:  Marilyn MacKay-Lyons; Gordon Gubitz; Nicholas Giacomantonio; Howard Wightman; David Marsters; Kara Thompson; Chris Blanchard; Gail Eskes; Marianne Thornton
Journal:  BMC Neurol       Date:  2010-12-08       Impact factor: 2.474

4.  High total hospitalization cost but low cost of imaging studies in recurrent acute ischemic stroke patients.

Authors:  Young Dae Kwon; Sung Sang Yoon; Hyejung Chang
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

Review 5.  The economic burden of stroke: a systematic review of cost of illness studies.

Authors:  Stefan Strilciuc; Diana Alecsandra Grad; Constantin Radu; Diana Chira; Adina Stan; Marius Ungureanu; Adrian Gheorghe; Fior-Dafin Muresanu
Journal:  J Med Life       Date:  2021 Sep-Oct

6.  Societal Cost of Ischemic Stroke in Romania: Results from a Retrospective County-Level Study.

Authors:  Stefan Strilciuc; Diana Alecsandra Grad; Vlad Mixich; Adina Stan; Anca Dana Buzoianu; Cristian Vladescu; Mihaela Adela Vintan
Journal:  Brain Sci       Date:  2021-05-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.